Integrin subunit alpha 3 (ITGA3) (ITGA3)

Integrin subunit alpha 3 (ITGA3) is a transmembrane protein that functions as a cell surface receptor for extracellular matrix components, particularly laminins (UniProt P26006). When paired with the integrin beta 1 subunit, it forms the VLA-3 complex, which is vital for cell adhesion, migration, and signaling processes (NCBI Gene 3675). ITGA3 mRNA expression is often dysregulated in various cancers, where it promotes epithelial-mesenchymal transition (EMT), tumor invasion, and metastasis (Ramovs et al., 2017, PMID: 29114095). Consequently, ITGA3 mRNA has emerged as a potential therapeutic target for RNA-interference (RNAi) strategies, such as siRNAs or antisense oligonucleotides, aimed at silencing its expression to inhibit cancer progression. Beyond oncology, mutations in the ITGA3 gene are linked to severe multi-organ disorders affecting the lungs, kidneys, and skin, known as ILNEB syndrome (Has et al., 2012, PMID: 22405085). Therapeutic development targeting ITGA3 must navigate the challenge of maintaining its critical physiological functions while effectively inhibiting its pathological roles in disease. Research has shown that silencing ITGA3 mRNA can significantly reduce the invasive potential of glioblastoma and colorectal cancer cells in preclinical models. While no ITGA3-specific drugs are currently FDA-approved, the target remains a high-interest candidate for precision medicine in metastatic disease.

Other names

CD49cVLA-3 subunit alphaVLA3GAPB3MSK18Antigen CD49CVLA-3 alpha subunit

Reduction of ITGA3 protein levels through mRNA degradation (via RNA interference or antisense inhibition) or blocking the functional protein-ligand interaction using monoclonal antibodies.